Literature DB >> 22205190

Ketamine as a novel antidepressant: from synapse to behavior.

J W Murrough1.   

Abstract

Recent reports of a rapid antidepressant effect of the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine, even in treatment-resistant populations, have spurred translational therapeutic and neuroscience research aimed at elucidating ketamine's mechanism of action. This article provides a concise overview of research findings that pertain to the effects of low-dose ketamine at the cellular, neurocircuitry, and behavioral levels and describes an integrated model of the action of ketamine in the treatment of depression.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22205190      PMCID： PMC3673880          DOI： 10.1038/clpt.2011.244

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  39 in total

1.  Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study.

Authors:  Laura M Rowland; Juan R Bustillo; Paul G Mullins; Rex E Jung; Rhoshel Lenroot; Elma Landgraf; Ranee Barrow; Ronald Yeo; John Lauriello; William M Brooks
Journal:  Am J Psychiatry       Date:  2005-02       Impact factor: 18.112

2.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

3.  Functional antagonists at the NMDA receptor complex exhibit antidepressant actions.

Authors:  R Trullas; P Skolnick
Journal:  Eur J Pharmacol       Date:  1990-08-21       Impact factor: 4.432

4.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

5.  Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

Authors:  F X Vollenweider; K L Leenders; C Scharfetter; A Antonini; P Maguire; J Missimer; J Angst
Journal:  Eur Neuropsychopharmacol       Date:  1997-02       Impact factor: 4.600

6.  Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans.

Authors:  Jaakko W Långsjö; Elina Salmi; Kaike K Kaisti; Sargo Aalto; Susanna Hinkka; Riku Aantaa; Vesa Oikonen; Tapio Viljanen; Timo Kurki; Martti Silvanto; Harry Scheinin
Journal:  Anesthesiology       Date:  2004-05       Impact factor: 7.892

Review 7.  Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression.

Authors:  P Skolnick; R T Layer; P Popik; G Nowak; I A Paul; R Trullas
Journal:  Pharmacopsychiatry       Date:  1996-01       Impact factor: 5.788

8.  Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans.

Authors:  Jaakko W Långsjö; Kaike K Kaisti; Sargo Aalto; Susanna Hinkka; Riku Aantaa; Vesa Oikonen; Hannu Sipilä; Timo Kurki; Martti Silvanto; Harry Scheinin
Journal:  Anesthesiology       Date:  2003-09       Impact factor: 7.892

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study.

Authors:  Matthew J Taylor; Eleanor R Tiangga; Roísín Ní Mhuircheartaigh; Philip J Cowen
Journal:  J Psychopharmacol       Date:  2011-05-26       Impact factor: 4.153
View more
  51 in total

Review 1.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 2.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

3.  Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

Authors:  James W Murrough; Le-Ben Wan; Brian Iacoviello; Katherine A Collins; Carly Solon; Benjamin Glicksberg; Andrew M Perez; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu; Katherine E Burdick
Journal:  Psychopharmacology (Berl)       Date:  2013-09-11       Impact factor: 4.530

4.  Sustained antidepressant response to ketamine.

Authors:  Onome Victor Atigari; David Healy
Journal:  BMJ Case Rep       Date:  2013-08-19

5.  Enduring effects of adolescent ketamine exposure on cocaine- and sucrose-induced reward in male and female C57BL/6 mice.

Authors:  Israel Garcia-Carachure; Francisco J Flores-Ramirez; Samuel A Castillo; Anapaula Themann; Miguel A Arenivar; Joshua Preciado-Piña; Arturo R Zavala; Mary Kay Lobo; Sergio D Iñiguez
Journal:  Neuropsychopharmacology       Date:  2020-03-12       Impact factor: 7.853

Review 6.  Pathogenesis of depression: Insights from human and rodent studies.

Authors:  C Ménard; G E Hodes; S J Russo
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

7.  Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder.

Authors:  Sarah M Szymkowicz; Nora Finnegan; Roman M Dale
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

8.  Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism.

Authors:  Valentina Gigliucci; Grainne O'Dowd; Sheena Casey; Danielle Egan; Sinead Gibney; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

9.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

10.  Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice.

Authors:  Marika V Doucet; Hester Levine; Kumlesh K Dev; Andrew Harkin
Journal:  Neuropsychopharmacology       Date:  2013-02-27       Impact factor: 7.853
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.